Search

Home > Biotech 2050 Podcast > 38. AI-driven early detection cancer screening from a blood test, Ken Chahine, CEO, Helio Health
Podcast: Biotech 2050 Podcast
Episode:

38. AI-driven early detection cancer screening from a blood test, Ken Chahine, CEO, Helio Health

Category: Science & Medicine
Duration: 00:22:24
Publish Date: 2020-11-11 13:00:18
Description: As Executive Vice President and General Manager of Ancestry.com, a 1.6 billion dollar technology company, Ken led the launch of AncestryDNA, a large-scale e-commerce genetic genealogy test with revenues of > $500M. In 2019, Ken led the launch AncestryHealth, an e-commerce LDT genetic health product on a next-generation sequencing (NGS) platform. Prior to Ancestry, he was the President and Chief Executive Officer at Avigen, a biopharmaceutical company that develops drugs for chronic neurological disorders, where he led the company in its mission to acquire, develop and commercialize innovative gene therapeutics. Dr. Chahine is a patent attorney and on the faculty at the University of Utah’s College of Law currently teaching new venture development, intellectual property and licensing. He earned a Ph.D. in Biochemistry from the University of Michigan, a J.D. from the University of Utah College of Law, and a B.A. in Chemistry from Florida State University.
Total Play: 0